Biodesix Cites 'Natural Fit' Of Acquired Integrated Diagnostics Lung Cancer Test
Executive Summary
Biodesix has acquired Integrated Diagnostics for an undisclosed sum to add the XL2 lung-cancer test to its molecular diagnostics line-up and to acquire technology and expertise that can improve its biopharma business.